Cargando…
Leveraging antigenic seniority for maternal vaccination to prevent mother-to-child transmission of HIV-1
The development of a maternal HIV vaccine to synergize with current antiretroviral drug prophylaxis can overcome implementation challenges and further reduce mother-to-child transmission (MTCT) of HIV. Both the epitope-specificity and autologous neutralization capacity of maternal HIV envelope (Env)...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338948/ https://www.ncbi.nlm.nih.gov/pubmed/35907918 http://dx.doi.org/10.1038/s41541-022-00505-w |
_version_ | 1784760075740512256 |
---|---|
author | Nelson, Ashley N. Dennis, Maria Mangold, Jesse F. Li, Katherine Saha, Pooja T. Cronin, Kenneth Cross, Kaitlyn A. Kumar, Amit Mangan, Riley J. Shaw, George M. Bar, Katharine J. Haynes, Barton Moody, Anthony M. Munir Alam, S. Pollara, Justin Hudgens, Michael G. Van Rompay, Koen K. A. De Paris, Kristina Permar, Sallie R. |
author_facet | Nelson, Ashley N. Dennis, Maria Mangold, Jesse F. Li, Katherine Saha, Pooja T. Cronin, Kenneth Cross, Kaitlyn A. Kumar, Amit Mangan, Riley J. Shaw, George M. Bar, Katharine J. Haynes, Barton Moody, Anthony M. Munir Alam, S. Pollara, Justin Hudgens, Michael G. Van Rompay, Koen K. A. De Paris, Kristina Permar, Sallie R. |
author_sort | Nelson, Ashley N. |
collection | PubMed |
description | The development of a maternal HIV vaccine to synergize with current antiretroviral drug prophylaxis can overcome implementation challenges and further reduce mother-to-child transmission (MTCT) of HIV. Both the epitope-specificity and autologous neutralization capacity of maternal HIV envelope (Env)-specific antibodies have been implicated in decreased risk of MTCT of HIV. Our goal was to determine if heterologous HIV Env immunization of SHIV.C.CH505-infected, ART-suppressed female rhesus macaques (RMs) could boost autologous Env-specific antibodies. SHIV.C.CH505-infected female RMs (n = 12), began a daily ART regimen at 12 weeks post-infection (wpi), which was continued for 12 weeks. Starting 2 weeks after ART initiation, RMs received 3 monthly immunizations with HIV b.63521/1086.C gp120 or placebo (n = 6/group) vaccine with adjuvant STR8S-C. Compared to the placebo-immunized animals, Env-vaccinated, SHIV-infected RMs exhibited enhanced IgG binding, avidity, and ADCC responses against the vaccine immunogens and the autologous SHIV.C.CH505 Env. Notably, the Env-specific memory B cells elicited by heterologous vaccination were dominated by cells that recognized the SHIV.C.CH505 Env, the antigen of primary exposure. Thus, vaccination of SHIV-infected, ART-suppressed RMs with heterologous HIV Envs can augment multiple components of the antibody response against the Env antigen of primary exposure, suggesting antigenic seniority. Our results suggest that a universal maternal HIV vaccination regimen can be developed to leverage antigenic seniority in targeting the maternal autologous virus pool. |
format | Online Article Text |
id | pubmed-9338948 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-93389482022-08-01 Leveraging antigenic seniority for maternal vaccination to prevent mother-to-child transmission of HIV-1 Nelson, Ashley N. Dennis, Maria Mangold, Jesse F. Li, Katherine Saha, Pooja T. Cronin, Kenneth Cross, Kaitlyn A. Kumar, Amit Mangan, Riley J. Shaw, George M. Bar, Katharine J. Haynes, Barton Moody, Anthony M. Munir Alam, S. Pollara, Justin Hudgens, Michael G. Van Rompay, Koen K. A. De Paris, Kristina Permar, Sallie R. NPJ Vaccines Article The development of a maternal HIV vaccine to synergize with current antiretroviral drug prophylaxis can overcome implementation challenges and further reduce mother-to-child transmission (MTCT) of HIV. Both the epitope-specificity and autologous neutralization capacity of maternal HIV envelope (Env)-specific antibodies have been implicated in decreased risk of MTCT of HIV. Our goal was to determine if heterologous HIV Env immunization of SHIV.C.CH505-infected, ART-suppressed female rhesus macaques (RMs) could boost autologous Env-specific antibodies. SHIV.C.CH505-infected female RMs (n = 12), began a daily ART regimen at 12 weeks post-infection (wpi), which was continued for 12 weeks. Starting 2 weeks after ART initiation, RMs received 3 monthly immunizations with HIV b.63521/1086.C gp120 or placebo (n = 6/group) vaccine with adjuvant STR8S-C. Compared to the placebo-immunized animals, Env-vaccinated, SHIV-infected RMs exhibited enhanced IgG binding, avidity, and ADCC responses against the vaccine immunogens and the autologous SHIV.C.CH505 Env. Notably, the Env-specific memory B cells elicited by heterologous vaccination were dominated by cells that recognized the SHIV.C.CH505 Env, the antigen of primary exposure. Thus, vaccination of SHIV-infected, ART-suppressed RMs with heterologous HIV Envs can augment multiple components of the antibody response against the Env antigen of primary exposure, suggesting antigenic seniority. Our results suggest that a universal maternal HIV vaccination regimen can be developed to leverage antigenic seniority in targeting the maternal autologous virus pool. Nature Publishing Group UK 2022-07-30 /pmc/articles/PMC9338948/ /pubmed/35907918 http://dx.doi.org/10.1038/s41541-022-00505-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Nelson, Ashley N. Dennis, Maria Mangold, Jesse F. Li, Katherine Saha, Pooja T. Cronin, Kenneth Cross, Kaitlyn A. Kumar, Amit Mangan, Riley J. Shaw, George M. Bar, Katharine J. Haynes, Barton Moody, Anthony M. Munir Alam, S. Pollara, Justin Hudgens, Michael G. Van Rompay, Koen K. A. De Paris, Kristina Permar, Sallie R. Leveraging antigenic seniority for maternal vaccination to prevent mother-to-child transmission of HIV-1 |
title | Leveraging antigenic seniority for maternal vaccination to prevent mother-to-child transmission of HIV-1 |
title_full | Leveraging antigenic seniority for maternal vaccination to prevent mother-to-child transmission of HIV-1 |
title_fullStr | Leveraging antigenic seniority for maternal vaccination to prevent mother-to-child transmission of HIV-1 |
title_full_unstemmed | Leveraging antigenic seniority for maternal vaccination to prevent mother-to-child transmission of HIV-1 |
title_short | Leveraging antigenic seniority for maternal vaccination to prevent mother-to-child transmission of HIV-1 |
title_sort | leveraging antigenic seniority for maternal vaccination to prevent mother-to-child transmission of hiv-1 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9338948/ https://www.ncbi.nlm.nih.gov/pubmed/35907918 http://dx.doi.org/10.1038/s41541-022-00505-w |
work_keys_str_mv | AT nelsonashleyn leveragingantigenicseniorityformaternalvaccinationtopreventmothertochildtransmissionofhiv1 AT dennismaria leveragingantigenicseniorityformaternalvaccinationtopreventmothertochildtransmissionofhiv1 AT mangoldjessef leveragingantigenicseniorityformaternalvaccinationtopreventmothertochildtransmissionofhiv1 AT likatherine leveragingantigenicseniorityformaternalvaccinationtopreventmothertochildtransmissionofhiv1 AT sahapoojat leveragingantigenicseniorityformaternalvaccinationtopreventmothertochildtransmissionofhiv1 AT croninkenneth leveragingantigenicseniorityformaternalvaccinationtopreventmothertochildtransmissionofhiv1 AT crosskaitlyna leveragingantigenicseniorityformaternalvaccinationtopreventmothertochildtransmissionofhiv1 AT kumaramit leveragingantigenicseniorityformaternalvaccinationtopreventmothertochildtransmissionofhiv1 AT manganrileyj leveragingantigenicseniorityformaternalvaccinationtopreventmothertochildtransmissionofhiv1 AT shawgeorgem leveragingantigenicseniorityformaternalvaccinationtopreventmothertochildtransmissionofhiv1 AT barkatharinej leveragingantigenicseniorityformaternalvaccinationtopreventmothertochildtransmissionofhiv1 AT haynesbarton leveragingantigenicseniorityformaternalvaccinationtopreventmothertochildtransmissionofhiv1 AT moodyanthonym leveragingantigenicseniorityformaternalvaccinationtopreventmothertochildtransmissionofhiv1 AT muniralams leveragingantigenicseniorityformaternalvaccinationtopreventmothertochildtransmissionofhiv1 AT pollarajustin leveragingantigenicseniorityformaternalvaccinationtopreventmothertochildtransmissionofhiv1 AT hudgensmichaelg leveragingantigenicseniorityformaternalvaccinationtopreventmothertochildtransmissionofhiv1 AT vanrompaykoenka leveragingantigenicseniorityformaternalvaccinationtopreventmothertochildtransmissionofhiv1 AT depariskristina leveragingantigenicseniorityformaternalvaccinationtopreventmothertochildtransmissionofhiv1 AT permarsallier leveragingantigenicseniorityformaternalvaccinationtopreventmothertochildtransmissionofhiv1 |